Category - Developments

Developments

Profound regains distribution rights for TULSA-PRO in Canada

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced that it has regained exclusive distribution rights for TULSA-PRO in Canada from Knight Therapeutics (TSX: GUD). Under the agreement established with Knight...

November 11, 2025

Developments

PharmaJet inks agreement with EVA Pharma to provide needle-free injection systems to support routine polio immunization in Egypt

Closely held PharmaJet has announced that it has signed a distribution agreement with ATR, an affiliate to closely held EVA Pharma. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes...

November 6, 2025

Developments

Advicenne submits registration application to FDA for Sibnayal in dRTA

Advicenne (Euronext Growth Paris: FR0013296746—ALDVI) has announced the submission of a registration application to the FDA for Sibnayal—a fixed-dose combination of potassium citrate and potassium bicarbonate—for the...

November 5, 2025

Developments

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Surmodics (NASDAQ: SRDX) has announced outcomes from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia in the PROWL registry study evaluating its Pounce thrombectomy platform. The...

November 5, 2025

Developments

Wellgistics enters LOI to acquire Kare RX digital hub

Wellgistics Health (NASDAQ: WGRX) has announced that it has entered into a non-binding letter of intent (LOI) to acquire Kare RX—an AI-based digital hub—from closely held Kare PharmaTech. According to Wellgistics, Kare...

November 5, 2025

Developments

GeoVax connects IDSA COVID-19 guidance to GEO-CM04S1 clinical data

GeoVax Labs (NASDAQ: GOVX) has highlighted that its recent Phase 2 findings for GEO-CM04S1 aligns with Infectious Diseases Society of America (IDSA) guidelines prioritizing vaccination for immunocompromised individuals...

October 29, 2025

Developments

APO grants new patent for Moleculin’s Annamycin

Moleculin Biotech (NASDAQ: MBRX) has announced that the Australian Patent Office (APO) has granted a patent with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity...

October 29, 2025

Developments

PharmaJet’s Tropis ID selected for Pakistan’s polio campaign

Closely held PharmaJet has announced that its WHO prequalified Tropis ID Needle-free Injection System will be used exclusively in Pakistan’s latest polio immunization campaign to deliver vaccines to 1.8 million children...

October 24, 2025

Developments

CorMedix receives innovative technology designation for DefenCath

CorMedix (NASDAQ: CRMD) has announced that its DefenCath antimicrobial catheter lock solution (CLS) has received innovative technology designation from closely held Vizient—a heathcare performance improvement company...

October 23, 2025

Developments

MAIA details exceptional survival in third-line NSCLC at ESMO

MAIA Biotechnology (NYSE American: MAIA) has announced highlights from a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany, showcasing its ongoing Phase 2 and Phase 3...

October 23, 2025

Category - Developments

Subscribe